Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Savara Inc.NASDAQ: SVRA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 253.28M shares rose 17.2% year over year, ahead of the +12.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.2% holds above the trailing-twelve-month pace of +12.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
253.28M+13.9% QoQ
Last fiscal yearDec 2025
222.39M+12.2% YoY
LTMMar 2026
227.14M+12.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.2%——
1 year+12.2%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
222.39M USD
Year-over-year change
+12.2%
4-year CAGR
+13.5%

Weighted Avg Shares vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's LTM Mar 2026 weighted avg shares of 227.14M shares is the highest of the 2 companies compared; the peer median is 50.71M shares.
  • Its year-over-year change of +12.3% is the highest of 2, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of +13.3% compares with a peer median of -11.9%.
SVRA Competitors Peer median
Weighted Avg Shares for SVRA and competitors
Company Period LTM YoY 3-year CAGR
SVRASavara Inc.LTM Mar 2026227.14M +12.3%+13.3%
TBPHTheravance Biopharma, Inc.LTM Mar 202650.71M +3.1%-11.9%
APMDApnimed, Inc.—— ——
Peer median (excluding SVRA) 50.71M+3.1%-11.9%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue28.99M27.88M44.26M78.03M245K
Gross Profit(28.99M)(27.88M)(44.26M)(78.03M)(245K)
Gross Margin—————
Research & Development28.99M27.88M44.26M78.03M81.4M
Selling, General & Admin12.35M10.93M15.67M25.04M42.06M
Operating Expenses12.49M10.96M15.75M25.17M123.3M
Depreciation & Amortization136K31K77K130K245K
EBITDA(40.5M)(38.01M)(59.13M)(102.27M)(118.59M)
EBITDA Margin—————
Operating Income(41.48M)(38.84M)(60.01M)(103.2M)(123.55M)
Operating Margin—————
Interest Income2.28K884.44M6.47M4.16M
Interest Expense2.28M88K000
Other Income / Expenses(1.54M)689K5.31M7.32M4.71M
Income Before Tax(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Net Margin—————
EPS (Basic)(0.32)(0.25)(0.33)(0.48)(0.53)
EPS (Diluted)(0.32)(0.25)(0.33)(0.48)(0.53)
Weighted Avg Shares133.92M152.77M165.2M198.19M222.39M
Weighted Avg Shares (Diluted)133.92M152.77M165.2M198.19M222.39M

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.